Laura Chico Analyst PerformanceManaging Director, Equity Research at WedbushLaura Chico is a stock analyst at Wedbush focused in the medical sector, covering 38 publicly traded companies. Over the past year, Laura Chico has issued 89 stock ratings, including strong buy, buy, hold, and sell recommendations. While full access to Laura Chico's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Laura Chico's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions. Analyst Rankings, Coverage, and Performance StatisticsAnalyst RankingSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings130 Last 8 YearsBuy Recommendations74.62% 97 Buy RatingsCompanies Covered38 Unique Companies Ratings Distribution130RatingsDistribution of strong buy, buy, hold, and sell ratings by Laura Chico.RatingPercentageCount Strong Buy0.8%1 ratings Buy73.8%96 ratings Hold20.8%27 ratings Sell4.6%6 ratingsOut of 130 total stock ratings issued by Laura Chico at Wedbush, the majority (73.8%) have been Buy recommendations, followed by 20.8% Hold, 4.6% Sell, and 0.8% Strong Buy.Best & Worst CallsBest Call0000.0%OVIDMar 2025Subscribe to MarketBeat All Access to get analyst recommendation ROI.Worst Call000.0%VTLDec 2017Subscribe to MarketBeat All Access to get analyst recommendation ROI.Exchange CoverageExchangePercentageCountNASDAQ89.5% of companies on NASDAQ34 companiesNYSE7.9% of companies on NYSE3 companiesOTCMKTS2.6% of companies on OTCMKTS1 companyLaura Chico, an analyst at Wedbush, currently covers 38 companies listed on NASDAQ, NYSE and OTCMKTS, with the majority traded on NASDAQ.Coverage FocusSector IconSectorPercentageMedical36 companies94.7%Construction1 company2.6%Computer and Technology1 company2.6%Laura Chico of Wedbush specializes in stock coverage within the Medical sector, with additional focus on Construction and Computer and Technology companies.Coverage IndustriesIndustryPercentageMED - BIOMED/GENE29 companies76.3%MED - DRUGS5 companies13.2%PHARMACEUTICAL PREPARATIONS2 companies5.3%BLDG - RSDNT/COMR1 company2.6%BUSINESS SOFTWARE SERVICES/BPO1 company2.6% About Laura ChicoLaura brings more than a decade of experience in the biotechnology and drug discovery industry, as well as nine years in Equity Research. During her career, Laura has served as Vice President Equity Research at Raymond James, and as a biotech analyst in the Robert W. Baird Equity Research Healthcare group. Before entering equity research, Laura held scientific roles in both industry and academic settings with focus in central nervous system (“CNS”) diseases such as Alzheimer’s disease. Laura received her B.S. in Bacteriology from the University of Wisconsin-Madison, her M.S. in Computational Biology & Bioinformatics, and her Ph.D. in Molecular Pharmacology, from Northwestern University. She continues to serve as an adjunct assistant professor at Northwestern University’s Feinberg School of Medicine.Follow on LinkedIn Laura Chico's Ratings History at Wedbush Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter Export CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsTVTXTravere Therapeutics6/3/2026Reiterated Rating$42.94$55.00Outperform$0.0000.00% ROIJBIOJade Biosciences6/2/2026Boost Price Target$18.59$45.00Outperform$0.0000.00% ROIPRAXPraxis Precision Medicines6/2/2026Lower Price Target$303.77$162.00Underperform$0.0000.00% ROIEWTXEdgewise Therapeutics6/1/2026Boost Price Target$40.26$52.00Outperform$0.0000.00% ROILRMRLarimar Therapeutics5/18/2026Lower Price Target$3.58$12.00Outperform$0.0000.00% ROIANROAlto Neuroscience5/14/2026Boost Price Target$22.94$24.00Neutral$0.0000.00% ROIPEPGPepGen5/13/2026Lower Price Target$1.61$4.00Outperform$0.0000.00% ROISLDBSolid Biosciences5/13/2026Lower Price Target$7.78$16.00Outperform$0.0000.00% ROIJBIOJade Biosciences5/11/2026Boost Price Target$25.81$34.00Outperform$0.0000.00% ROICLYMClimb Bio5/8/2026Boost Price Target$11.94$17.00Outperform$0.0000.00% ROI Get the Latest News and Ratings for Your StocksEnter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. PRAXPraxis Precision Medicines5/8/2026Boost Price Target$334.73$166.00Underperform$0.0000.00% ROIDNLIDenali Therapeutics5/8/2026Lower Price Target$19.89$23.00Outperform$0.0000.00% ROIBCRXBioCryst Pharmaceuticals5/7/2026Lower Price Target$8.66$21.00Outperform$0.0000.00% ROIDNTHDianthus Therapeutics5/6/2026Boost Price Target$90.24$105.00Outperform$0.0000.00% ROIRAREUltragenyx Pharmaceutical5/6/2026Lower Price Target$25.01$26.00Neutral$0.0000.00% ROINBIXNeurocrine Biosciences5/6/2026Boost Price Target$135.06$176.00Outperform$0.0000.00% ROITVTXTravere Therapeutics5/5/2026Boost Price Target$44.91$55.00Outperform$0.0000.00% ROISIONSionna Therapeutics5/5/2026Initiated Coverage$40.45$53.00Outperform$0.0000.00% ROISIONSionna Therapeutics5/4/2026Upgrade$40.97Strong-Buy$0.0000.00% ROIBIIBBiogen4/30/2026Boost Price Target$194.38$196.00Neutral$0.0000.00% ROIOVIDOvid Therapeutics4/15/2026Reiterated Rating$2.96$7.00Outperform$0.0000.00% ROITVTXTravere Therapeutics4/14/2026Boost Price Target$41.18$44.00Outperform$0.0000.00% ROIVRDNViridian Therapeutics4/8/2026Lower Price Target$13.96$31.00Outperform$0.0000.00% ROIPHVSPharvaris4/7/2026Boost Price Target$28.37$42.00Outperform$0.0000.00% ROINBIXNeurocrine Biosciences4/7/2026Boost Price Target$132.48$166.00Outperform$0.0000.00% ROIANROAlto Neuroscience4/2/2026Lower Price Target$20.41$21.00Neutral$0.0000.00% ROIVRDNViridian Therapeutics3/31/2026Lower Price Target$18.82$37.00Outperform$0.0000.00% ROIPEPGPepGen3/31/2026Lower Price Target$1.44$5.00Outperform$0.0000.00% ROILRMRLarimar Therapeutics3/20/2026Boost Price Target$4.47$13.00Outperform$0.0000.00% ROIOVIDOvid Therapeutics3/20/2026Boost Price Target$2.30$7.00Outperform$0.0000.00% ROIEWTXEdgewise Therapeutics3/17/2026Reiterated Rating$29.78$32.00Outperform$0.0000.00% ROISTOKStoke Therapeutics3/17/2026Boost Price Target$33.96$38.00Outperform$0.0000.00% ROIANROAlto Neuroscience3/17/2026Boost Price Target$24.27$22.00Neutral$0.0000.00% ROIXENEXenon Pharmaceuticals3/16/2026Lower Price Target$55.23$63.00Outperform$0.0000.00% ROIMAZEMaze Therapeutics3/16/2026Boost Price Target$50.21$58.00Outperform$0.0000.00% ROIVRDNViridian Therapeutics3/11/2026Reiterated Rating$29.19$44.00Outperform$0.0000.00% ROISLDBSolid Biosciences3/11/2026Reiterated Rating$8.18$14.00Outperform$0.0000.00% ROIXENEXenon Pharmaceuticals3/10/2026Boost Price Target$62.76$64.00Outperform$0.0000.00% ROIDNTHDianthus Therapeutics3/10/2026Boost Price Target$79.23$80.00Outperform$0.0000.00% ROIJBIOJade Biosciences3/9/2026Reiterated Rating$14.05$24.00Outperform$0.0000.00% ROIStranded On The Flood Plains of History (Ad)The petrodollar arrangement that Kissinger brokered in 1974 officially expired in June 2024. China has slashed U.S. Treasury holdings by 45% from peak, and central banks are swapping dollars for gold at the fastest pace since the Cold War. Porter Stansberry believes Trump is channeling more than $3 trillion toward securing the minerals, chips, and infrastructure that make AI possible - and companies at those chokepoints like Vertiv (up 500%), GE Vernova (up 700%), and Arista Networks (up 750%) are already moving. Porter's new briefing names one asset to buy today plus five stocks positioned at the narrowest chokepoints of what he calls the Silicon Dollar.Read Porter's full briefing and get the ticker names todayCLYMClimb Bio3/5/2026Initiated Coverage$7.28$12.00Outperform$0.0000.00% ROILRMRLarimar Therapeutics3/3/2026Boost Price Target$5.36$12.00Outperform$0.0000.00% ROILRMRLarimar Therapeutics2/25/2026Reiterated Rating$3.69$11.00Outperform$0.0000.00% ROIAPLSApellis Pharmaceuticals2/25/2026Lower Price Target$22.13$18.00Neutral$0.0000.00% ROIGOSSGossamer Bio2/24/2026Reiterated Rating$0.42$1.00Neutral$0.0000.00% ROIARDXArdelyx2/23/2026Reiterated Rating$5.73$19.00Outperform$0.0000.00% ROIPRAXPraxis Precision Medicines2/20/2026Boost Price Target$331.61$130.00Underperform$0.0000.00% ROIRAREUltragenyx Pharmaceutical2/17/2026Reiterated Rating$20.66$25.00Neutral$0.0000.00% ROINBIXNeurocrine Biosciences2/12/2026Boost Price Target$126.00$151.00Outperform$0.0000.00% ROIDNTHDianthus Therapeutics2/11/2026Boost Price Target$49.44$55.00Outperform$0.0000.00% ROIBIIBBiogen2/9/2026Boost Price Target$201.18$187.00Neutral$0.0000.00% ROIARDXArdelyx1/21/2026Boost Price Target$7.76$19.00Outperform$0.0000.00% ROISTOKStoke Therapeutics1/12/2026Boost Price Target$32.85$36.00Outperform$0.0000.00% ROIPRAXPraxis Precision Medicines1/12/2026Boost Price Target$288.45$95.00Underperform$0.0000.00% ROIDNTHDianthus Therapeutics12/22/2025Reiterated Rating$42.44$46.00Outperform$0.0000.00% ROIVERAVera Therapeutics12/11/2025Boost Price Target$44.34$33.00Neutral$0.0000.00% ROIDNLIDenali Therapeutics12/11/2025Lower Price Target$17.49$30.00Outperform$0.0000.00% ROIVRDNViridian Therapeutics12/10/2025Boost Price Target$31.80$47.00Outperform$0.0000.00% ROIDNLIDenali Therapeutics12/5/2025Boost Price Target$20.11$31.00Outperform$0.0000.00% ROIPRAXPraxis Precision Medicines12/5/2025Reiterated Rating$189.97$83.00Underperform$0.0000.00% ROIARDXArdelyx11/25/2025Downgrade$5.50Hold$0.0000.00% ROIPHVSPharvaris11/13/2025Boost Price Target$26.13$30.00Outperform$0.0000.00% ROIMAZEMaze Therapeutics11/7/2025Boost Price Target$29.21$36.00Outperform$0.0000.00% ROIEWTXEdgewise Therapeutics11/7/2025Lower Price Target$17.58$32.00Outperform$0.0000.00% ROIDNTHDianthus Therapeutics11/6/2025Boost Price Target$33.73$46.00Outperform$0.0000.00% ROIPRAXPraxis Precision Medicines11/6/2025Boost Price Target$164.64$77.00Underperform$0.0000.00% ROISTOKStoke Therapeutics11/5/2025Boost Price Target$21.20$32.00Outperform$0.0000.00% ROIATXSAstria Therapeutics10/15/2025Set Price Target$11.61$13.00Neutral$0.0000.00% ROIATXSAstria Therapeutics10/15/2025Downgrade$11.92$13.00Neutral$0.0000.00% ROILRMRLarimar Therapeutics9/30/2025Lower Price Target$3.38$11.00Outperform$0.0000.00% ROIPEPGPepGen9/25/2025Boost Price Target$5.97$9.00Outperform$0.0000.00% ROINBIXNeurocrine Biosciences9/22/2025Reiterated Rating$146.62Outperform$0.0000.00% ROIDNTHDianthus Therapeutics9/12/2025Boost Price Target$37.86$44.00Outperform$0.0000.00% ROITRMLTourmaline Bio9/9/2025Downgrade$30.18$48.00Neutral$0.0000.00% ROIDNTHDianthus Therapeutics8/21/2025Boost Price Target$23.72$42.00Outperform$0.0000.00% ROIJBIOJade Biosciences8/14/2025Boost Price Target$7.03$18.00Outperform$0.0000.00% ROISLDBSolid Biosciences8/13/2025Lower Price Target$6.15$14.00Outperform$0.0000.00% ROISTOKStoke Therapeutics8/13/2025Boost Price Target$15.66$22.00Outperform$0.0000.00% ROIXENEXenon Pharmaceuticals8/12/2025Boost Price Target$36.10$43.00Outperform$0.0000.00% ROITVTXTravere Therapeutics8/7/2025Boost Price Target$17.24$32.00Outperform$0.0000.00% ROIGOSSGossamer Bio8/6/2025Boost Price Target$1.97$5.00Outperform$0.0000.00% ROIARDXArdelyx8/5/2025Reiterated Rating$5.08$14.00Outperform$0.0000.00% ROINBIXNeurocrine Biosciences7/31/2025Boost Price Target$136.76$141.00Outperform$0.0000.00% ROIRAREUltragenyx Pharmaceutical7/14/2025Lower Price Target$29.51$34.00Neutral$0.0000.00% ROIMAZEMaze Therapeutics7/8/2025Initiated Coverage$12.12$17.00Outperform$0.0000.00% ROILRMRLarimar Therapeutics6/24/2025Lower Price Target$2.76$15.00Outperform$0.0000.00% ROILENLennar6/18/2025Reiterated Rating$105.15$130.00Neutral$0.0000.00% ROIBIIBBiogen6/12/2025Reiterated Rating$132.63$121.00Neutral$0.0000.00% ROIPHVSPharvaris6/5/2025Reiterated Rating$16.88$27.00Outperform$0.0000.00% ROIVIGLVigil Neuroscience5/22/2025Downgrade$2.31$8.00Hold$0.0000.00% ROITrump’s New Dollar revealed (Ad)The last time something like this happened was 1974 - a secret deal that quietly determined the financial fate of an entire generation. According to Porter Stansberry, founder of one of the largest independent financial research firms in the world, it is happening again. Fortune calls it 'the biggest change to the world's relationship with the dollar' in a generation. Stansberry says Trump's money reset - enacted through executive orders and a treaty signed by 13 nations in December 2025 called Pax Silica - could determine whether you are enriched or quietly impoverished by the shift already underway.Read Porter Stansberry's full briefing and find out which moves to make nowTVTXTravere Therapeutics5/16/2025Reiterated Rating$17.51$30.00Outperform$00.0000.00% ROIGOSSGossamer Bio5/16/2025Reiterated Rating$1.08$4.00Outperform$0.0000.00% ROIANROAlto Neuroscience5/15/2025Reiterated Rating$2.26$4.00Neutral$00.0000.00% ROIDNLIDenali Therapeutics5/7/2025Lower Price Target$14.02$30.00Outperform$00.0000.00% ROIVERAVera Therapeutics5/7/2025Lower Price Target$22.33$26.00Neutral$00.0000.00% ROIVIGLVigil Neuroscience5/5/2025Reiterated Rating$2.85$13.00Outperform$0.0000.00% ROITVTXTravere Therapeutics5/2/2025Reiterated Rating$20.56$30.00Outperform$00.0000.00% ROIEWTXEdgewise Therapeutics4/21/2025Reiterated Rating$13.67$43.00Outperform$00.0000.00% ROIVIGLVigil Neuroscience3/14/2025Lower Price Target$2.15$13.00Outperform$0.0000.00% ROIGOSSGossamer Bio3/14/2025Reiterated Rating$1.35$4.00Outperform$0.0000.00% ROIOVIDOvid Therapeutics3/12/2025Reiterated Rating$0.49$3.00Outperform$0.0000.00% ROIATXSAstria Therapeutics3/12/2025Reiterated Rating$6.47$28.00Outperform$0.0000.00% ROIDNTHDianthus Therapeutics3/12/2025Reiterated Rating$22.69$36.00Outperform$00.0000.00% ROITRMLTourmaline Bio3/6/2025Initiated Coverage$12.90$42.00Outperform$0.0000.00% ROIAPLSApellis Pharmaceuticals3/3/2025Lower Price Target$25.15$29.00Neutral$00.0000.00% ROISAGESage Therapeutics2/12/2025Reiterated Rating$7.24$6.00Neutral$0.0000.00% ROINBIXNeurocrine Biosciences2/7/2025Lower Price Target$121.12$147.00Outperform$000.0000.00% ROIRAREUltragenyx Pharmaceutical1/13/2025Reiterated Rating$41.84$48.00Neutral$00.0000.00% ROI Stock Forecasts and Research Tools Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Top Stock Recommendations by BrokerageWall Street ZenCitigroupRoyal Bank Of CanadaJPMorgan Chase & Co.Jefferies Financial GroupThe Goldman Sachs GroupEvercoreCanaccord Genuity GroupKeyCorpBerenberg BankSanford C. BernsteinShore Capital GroupWilliam BlairUBS GroupBarclays Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.